We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

MaxCyte

Picking up the pace

Update | 15 January 2019

Nexstim

Achieving commendable outcomes in depression

Update | 20 December 2018

e-therapeutics

First commercial deal secured with global diabetes leader

Update | 10 December 2018

Mereo BioPharma

Merger with NASDAQ-listed OncoMed

Lighthouse | 07 December 2018

e-therapeutics

New insights from Parkinson’s disease collaboration

Update | 06 December 2018

MaxCyte

Momentum building in Cell Therapy and CARMA

Outlook | 05 December 2018

Scancell

Opening new pathways in immuno-oncology

Initiation | 28 November 2018

BerGenBio

Advancing towards randomised studies

Update | 26 November 2018

Bonesupport

Key CERTiFy study confirms CERAMENT’s properties

Update | 19 November 2018

Tissue Regenix Group

Arthrex collaboration extended into Europe

Update | 13 November 2018
1 2 3 4 5 6 7 8 9 10
98 results found.